Verition Fund Management’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
Other funds holding PTCT
RI
JT
Verition Fund Management's PTCT Position: Q2 2026 in Review
Verition Fund Management opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 15,000 shares worth $1.22M. The stake represents 0.01% of the portfolio and ranks #1351 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in PTCT as recently as Q4 2025.
Verition Fund Management first reported a position in PTCT in Q1 2018 and has held it in 20 quarters since. The position peaked at $5.64M in Q2 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- Verition Fund Management held 15,000 shares of PTC Therapeutics worth $1.22M as of Q2 2026.
- PTC Therapeutics was a new Verition Fund Management position in Q2 2026.
- PTC Therapeutics made up 0.01% of Verition Fund Management's portfolio in Q2 2026, its #1351 holding.
- Verition Fund Management first reported a position in PTC Therapeutics in Q1 2018 and has held it in 20 quarters since.
- Verition Fund Management's PTC Therapeutics position peaked at $5.64M in Q2 2025.
- 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.